Meyers J, Hoog M, Mody R, Yu M, Davis K. The health care resource utilization and costs among patients with type 2 diabetes and either cardiovascular disease or cardiovascular risk factors an analysis of a US health insurance database. Clin Ther. 2021 Nov;43(11):1827-42. doi: 10.1016/j.clinthera.2021.09.003
Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P. Insights into patients' experience with Type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019 Nov;41(11):2219-2230. doi: 10.1016/j.clinthera.2019.09.003
Caro JJ, Klittich WS, Raggio G, Kavanagh PL, O'Brien JA, Shomphe LA, Flegel KM, Copley-Merriman C, Sigler C. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther. 2000 Jan;22(1):116-27.